$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate Merger of DNOW, TASK, SQCF, and YMAB
NEW YORK, Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC ( the "M&A Class Action Firm" ) , has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: WideOpenWest, Inc. ( NYSE - WOW ) , BankFinancial Corporation ( Nasdaq - BFIN ) , STAAR Surgical Company ( Nasdaq - STAA ) , Y-mAbs Therapeutics, Inc. ( Nasdaq - YMAB )
BALA CYNWYD, Pa., Aug. 12, 2025 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
Y-mAbs Therapeutics, Inc. ( YMAB ) Reports Q2 Loss, Tops Revenue Estimates
YmAbs Therapeutics (YMAB) delivered earnings and revenue surprises of +74.07% and +5.96%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Y-mAbs ( YMAB ) Q2 Revenue Falls 14%
Y-mAbs Therapeutics ( NASDAQ:YMAB ) , a biopharmaceutical company focused on developing and commercializing antibody-based cancer therapies, reported its second quarter 2025 results on August 8, 2025. The company beat expectations on both revenue and earnings per share, posting GAAP revenue of ...
Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments
PRINCETON, N.J., Aug. 08, 2025 ( GLOBE NEWSWIRE ) -- Y-mAbs Therapeutics, Inc. ( the "Company" or "Y-mAbs" ) ( Nasdaq: YMAB ) , a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for ...
Celldex Therapeutics ( CLDX ) Reports Q2 Loss, Misses Revenue Estimates
Celldex (CLDX) delivered earnings and revenue surprises of +1.16% and -56.18%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025 - Y-mAbs Therapeutics ( NASDAQ:YMAB )
PRINCETON, N.J., Aug. 07, 2025 ( GLOBE NEWSWIRE ) -- Y-mAbs Therapeutics, Inc. ( the "Company" or "Y-mAbs" ) YMAB, a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody-based therapeutics for the treatment of cancer, today announced it will ...
Keros Therapeutics, Inc. ( KROS ) Reports Q2 Loss, Beats Revenue Estimates
Keros Therapeutics (KROS) delivered earnings and revenue surprises of +33.33% and +135.95%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
YmAbs Therapeutics ( YMAB ) Surges 103.3%: Is This an Indication of Further Gains?
YmAbs Therapeutics (YMAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates STAA, YMAB, BASE, CORZ on Behalf of Shareholders - Core Scientific ( NASDAQ:CORZ ) , Couchbase ( NASDAQ:BASE )
NEW YORK, Aug. 05, 2025 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Nasdaq Down 50 Points; ISM Services PMI Declines In July - Ameresco ( NYSE:AMRC ) , Agilon Health ( NYSE:AGL )
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling around 50 points on Tuesday. The Dow traded up 0.12% to 44,228.65 while the NASDAQ declined 0.24% to 21,003.87. The S&P 500 also fell, dropping, 0.15% to 6,320.30. Consumer staples shares jumped by 0.4% on Tuesday.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: STAAR Surgical Company ( Nasdaq - STAA ) , Y-mAbs Therapeutics, Inc. ( Nasdaq - YMAB ) , Couchbase, Inc. ( Nasdaq - BASE ) , Core Scientific, Inc. ( Nasdaq - CORZ )
BALA CYNWYD, Pa., Aug. 05, 2025 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
Dow Surges Over 100 Points; Pfizer Earnings Top Views - Agilon Health ( NYSE:AGL ) , Ichor Holdings ( NASDAQ:ICHR )
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 100 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.25% to 44,285.50 while the NASDAQ climbed 0.25% to 21,106.41. The S&P 500 also rose, gaining, 0.19% to 6,341.77.
SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics - Y-mAbs Therapeutics ( NASDAQ:YMAB )
Acquisition to Include Naxitamab-gqgk DANYELZA® ( Naxitamab-gqgk ) , Further Broadening SERB's Rare Oncology Product Portfolio Transaction Expands SERB's Investment in the U.S. SERB to Commence All-Cash Tender Offer to Acquire All Outstanding Shares of Y-mAbs for $8.60 Per Share
YmAbs Therapeutics ( YMAB ) Upgraded to Buy: Here's What You Should Know
YmAbs Therapeutics (YMAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline
PRINCETON, N.J., May 28, 2025 ( GLOBE NEWSWIRE ) -- Y-mAbs Therapeutics, Inc. ( the "Company" or "Y-mAbs" ) ( Nasdaq: YMAB ) , a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radiopharmaceuticals, and commercial stage antibody-based ...
Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting - Y-mAbs Therapeutics ( NASDAQ:YMAB )
PRINCETON, N.J., May 26, 2025 ( GLOBE NEWSWIRE ) -- Y-mAbs Therapeutics, Inc. ( the "Company" or "Y-mAbs" ) YMAB, a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of ...
Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting
PRINCETON, N.J., May 26, 2025 ( GLOBE NEWSWIRE ) -- Y-mAbs Therapeutics, Inc. ( the "Company" or "Y-mAbs" ) ( Nasdaq: YMAB ) , a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the ...
Y-mAbs Therapeutics, Inc. ( YMAB ) Reports Q1 Loss, Tops Revenue Estimates
YmAbs Therapeutics (YMAB) delivered earnings and revenue surprises of 45.45% and 6.92%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Y-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025 - Y-mAbs Therapeutics ( NASDAQ:YMAB )
PRINCETON, N.J., May 13, 2025 ( GLOBE NEWSWIRE ) -- Y-mAbs Therapeutics, Inc. ( the "Company" or "Y-mAbs" ) YMAB, a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of ...
Tango Therapeutics, Inc. ( TNGX ) Reports Q1 Loss, Lags Revenue Estimates
Tango Therapeutics (TNGX) delivered earnings and revenue surprises of -5.88% and 13.94%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Anika Therapeutics ( ANIK ) Reports Q1 Loss, Misses Revenue Estimates
Anika (ANIK) delivered earnings and revenue surprises of -166.67% and 8.50%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Qiagen ( QGEN ) Q1 Earnings and Revenues Surpass Estimates
Qiagen (QGEN) delivered earnings and revenue surprises of 10% and 4.18%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Y-mAbs Announces Update to National Comprehensive Cancer Network® ( NCCN® ) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk ( DANYELZA® )
PRINCETON, N.J., May 07, 2025 ( GLOBE NEWSWIRE ) -- Y-mAbs Therapeutics, Inc. ( the "Company" or "Y-mAbs" ) ( Nasdaq: YMAB ) , a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the ...
Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025 - Y-mAbs Therapeutics ( NASDAQ:YMAB )
PRINCETON, N.J., May 06, 2025 ( GLOBE NEWSWIRE ) -- Y-mAbs Therapeutics, Inc. ( the "Company" or "Y-mAbs" ) YMAB, a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of ...
Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025
PRINCETON, N.J., May 06, 2025 ( GLOBE NEWSWIRE ) -- Y-mAbs Therapeutics, Inc. ( the "Company" or "Y-mAbs" ) ( Nasdaq: YMAB ) , a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the ...
Earnings Preview: Acadia Pharmaceuticals ( ACAD ) Q1 Earnings Expected to Decline
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Y-mAbs Therapeutics, Inc. ( YMAB ) Q1 Earnings Expected to Decline
YmAbs Therapeutics (YMAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research ( AACR ) Annual Meeting
NEW YORK, April 27, 2025 ( GLOBE NEWSWIRE ) -- Y-mAbs Therapeutics, Inc. ( the "Company" or "Y-mAbs" ) ( Nasdaq: YMAB ) , a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the ...
Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research ( AACR ) Annual Meeting - Y-mAbs Therapeutics ( NASDAQ:YMAB )
NEW YORK, April 27, 2025 ( GLOBE NEWSWIRE ) -- Y-mAbs Therapeutics, Inc. ( the "Company" or "Y-mAbs" ) YMAB, a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of ...
Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma
NEW YORK, April 25, 2025 ( GLOBE NEWSWIRE ) -- Y-mAbs Therapeutics, Inc. ( the "Company" or "Y-mAbs" ) ( Nasdaq: YMAB ) , a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the ...
Y-mAbs Therapeutics, Inc. ( YMAB ) Reports Q4 Loss, Lags Revenue Estimates
YmAbs Therapeutics (YMAB) delivered earnings and revenue surprises of -15.38% and 0.40%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments
• Reported Total Revenues of $26.5 million for the fourth quarter of 2024 and $87.7 million for the full year 2024 • The Company established two business units in January 2025 aimed to accelerate the clinical development of its Radiopharmaceuticals Platform and optimize the commercial potential ...
Iovance Biotherapeutics ( IOVA ) Reports Q4 Loss, Tops Revenue Estimates
Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of 3.70% and 2.26%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Y-mAbs Therapeutics, Inc. ( YMAB ) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
YmAbs Therapeutics (YMAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Y-mAbs to Present at the Oppenheimer 35ᵗʰ Annual Life Sciences Conference
NEW YORK, Feb. 06, 2025 ( GLOBE NEWSWIRE ) -- Y-mAbs Therapeutics, Inc. ( the "Company" or "Y-mAbs" ) ( Nasdaq: YMAB ) , a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the ...
YmAbs Therapeutics ( YMAB ) Loses -25.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for YmAbs Therapeutics (YMAB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend ...
YmAbs Therapeutics ( YMAB ) Loses -26.93% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
YmAbs Therapeutics (YMAB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting
NEW YORK, Jan. 31, 2025 ( GLOBE NEWSWIRE ) -- Y-mAbs Therapeutics, Inc. ( the "Company" or "Y-mAbs" ) ( Nasdaq: YMAB ) , a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the ...
Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting - Y-mAbs Therapeutics ( NASDAQ:YMAB )
NEW YORK, Jan. 31, 2025 ( GLOBE NEWSWIRE ) -- Y-mAbs Therapeutics, Inc. ( the "Company" or "Y-mAbs" ) YMAB, a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of ...
Correcting & Replacing - Y-mAbs Provides Strategic Business Update and 2025 Priorities - Y-mAbs Therapeutics ( NASDAQ:YMAB )
Company establishes two business units with goal of accelerating clinical development of its Radiopharmaceuticals Platform and optimizing the commercial potential of DANYELZA Preliminary Part A data from GD2-SADA Phase 1 trial demonstrates tolerability and validity of SADA PRIT platform ...
Correcting & Replacing - Y-mAbs Provides Strategic Business Update and 2025 Priorities
Company establishes two business units with goal of accelerating clinical development of its Radiopharmaceuticals Platform and optimizing the commercial potential of ...
Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit
NEW YORK, Jan. 10, 2025 ( GLOBE NEWSWIRE ) -- Y-mAbs Therapeutics, Inc. ( the "Company" or "Y-mAbs" ) ( Nasdaq: YMAB ) , a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the ...
Y-mAbs Provides Strategic Business Update and 2025 Priorities - Y-mAbs Therapeutics ( NASDAQ:YMAB )
Company establishes two business units with goal of accelerating the advancement of its Radiopharmaceuticals Platform and optimizing the commercial potential of DANYELZA Preliminary Part A data from GD2-SADA Phase 1 trial demonstrates tolerability and validity of SADA PRIT platform pre-targeting ...
Y-mAbs Provides Strategic Business Update and 2025 Priorities
Company establishes two business units with goal of accelerating the advancement of its Radiopharmaceuticals Platform and optimizing the commercial potential of ...
Acelyrin, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - NeuroPace ( NASDAQ:NPCE ) , Cogent Biosciences ( NASDAQ:COGT )
U.S. stock futures were mostly higher this morning, with the Dow futures gaining around 0.1% on Tuesday. Shares of Acelyrin, Inc. SLRN fell sharply in today's pre-market trading. ACELYRIN announced additional Phase 2 data and the Phase 3 program design for lonigutamab in Thyroid Eye Disease.
Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Y-mAbs Therapeutics ( NASDAQ:YMAB )
NEW YORK, Dec. 23, 2024 ( GLOBE NEWSWIRE ) -- Y-mAbs Therapeutics, Inc. ( the "Company" or "Y-mAbs" ) YMAB, a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of ...
Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology ( ASH ) Annual Meeting
NEW YORK, Dec. 07, 2024 ( GLOBE NEWSWIRE ) -- Y-mAbs Therapeutics, Inc. ( the "Company" or "Y-mAbs" ) ( Nasdaq: YMAB ) , a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the ...
Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology ( ASH ) Annual Meeting - Y-mAbs Therapeutics ( NASDAQ:YMAB )
NEW YORK, Dec. 07, 2024 ( GLOBE NEWSWIRE ) -- Y-mAbs Therapeutics, Inc. ( the "Company" or "Y-mAbs" ) YMAB, a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of ...
Y-mAbs to Participate at Citi's 2024 Global Healthcare Conference - Y-mAbs Therapeutics ( NASDAQ:YMAB )
NEW YORK, Nov. 27, 2024 ( GLOBE NEWSWIRE ) -- Y-mAbs Therapeutics, Inc. ( the "Company" or "Y-mAbs" ) YMAB, a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of ...
